-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On July 19, the China Securities Regulatory Commission issued an agreement on the approval of CITIC Mobile Communication Technology .
, L.
, Shanghai Xuantai Pharmaceutical Technology .
, L.
, Shanghai United Imaging Medical Technology .
, L.
, and Guizhou Zhenhua Scenery Semiconductor .
, L.
The approval of the company's initial public offering of stock registration, and the approval of the above-mentioned four companies' initial public offering of stocks and registration applications for listing on the Science and Technology Innovation Boa.
Xuantai Pharmaceutical and United Imaging Medical are pharmaceutical compani.
Among them, Xuantai Pharmaceutical is an enterprise driven by R&D and innovation, mainly engaged in the R&D, production and sales of high-end preparations, as well as CRO servic.
Relying on years of technical accumulation, Xuantai Medicine has formed three major technology platforms, namely, "Insoluble Drug Solubilization Technology Platform", "Sustained and Controlled Release Drug Preparation Research and Development Platform" and "Fixed-dose Compound Drug Preparation Research and Development Platfor.
According to the prospectus of Xuantai Pharmaceuticals, Xuantai Pharmaceuticals plans to issue 434 million shares in an initial public offering and raise 600 million yuan, which will be mainly used for the preparation production complex building and related supporting facilities projects, high-end generic drugs and improved new drug research and development projects and supplementary Liquidi.
The fundraising project aims to increase the company's production capacity, improve the technical level, enrich the product line, and provide financial suppo.
At the same time, the implementation of the project is also conducive to further enhancing the innovation and creativity of the company's existing products, thereby enhancing the company's sustainable profitability and overall competitivene.
It is understood that Xuantai Pharmaceutical has achieved rapid development in recent years under the background of favorable policies supported by the country's key support for the preparation indust.
The data shows that by the end of 2021, Xuantai Pharmaceutical has completed 4 ANDA applications and 6 NMPA applications for its self-developed products in the field of high-end generic drugs; the high-end generic drugs jointly developed by Xuantai have completed 2 ANDA applications and 3 NMPA applicatio.
, In addition, the company has a number of improved new drug projects under developme.
From the performance point of view, the data shows that from 2019 to 2021, Xuantai Pharmaceutical relies on core technologies to achieve main business income of 138 million yuan, 316 million yuan and 314 million yuan respective.
United Imaging Medical is an enterprise that designs, develops, produces and sells high-end medical imaging diagnostic products, radiotherapy products and high-end life science instruments, and provides supporting intelligent and information-based solutio.
The company has outstanding scientific research strength, and has invested more than 5 billion yuan in research and development in the past three yea.
According to the prospectus of United Imaging Medical, it plans to raise funds of 148 billion yuan this time, which will be used for next-generation product research and development projects, high-end medical imaging equipment industrialization fund projects, informatization improvement projects and supplementary working capital, e.
, to further support the company's future developme.
Scale and globalization, expand the company's high-end medical imaging equipment production capacity, accelerate the company's product and technology upgrades, improve the localization level of core components, and expand the company's domestic and foreign marke.
It is understood that United Imaging Medical has already deployed production capacity in Shanghai, Changzhou, Wuhan, Houston, USA, e.
It has also set up future laboratories at its Shanghai headquarters and Houston, USA, focusing on the pre-research, cross-border and advanced technology of next-generation imaging and treatment equipme.
Industry technological breakthroughs and their innovative applications in the medical fie.
In terms of globalization, since 2018, the proportion of overseas revenue in United Imaging's main business has shown an increasing trend year by ye.
United Imaging Medical has obtained FDA certificates for 22 products and CE certificates for 34 produc.
In terms of performance, from 2019 to 2021, the compound growth rate of United Imaging Medical's operating income reached 50
In the past three years, the company's operating income was 980 billion yuan, 761 billion yuan, and 254 billion yuan respective.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
, L.
, Shanghai Xuantai Pharmaceutical Technology .
, L.
, Shanghai United Imaging Medical Technology .
, L.
, and Guizhou Zhenhua Scenery Semiconductor .
, L.
The approval of the company's initial public offering of stock registration, and the approval of the above-mentioned four companies' initial public offering of stocks and registration applications for listing on the Science and Technology Innovation Boa.
Xuantai Pharmaceutical and United Imaging Medical are pharmaceutical compani.
Among them, Xuantai Pharmaceutical is an enterprise driven by R&D and innovation, mainly engaged in the R&D, production and sales of high-end preparations, as well as CRO servic.
Relying on years of technical accumulation, Xuantai Medicine has formed three major technology platforms, namely, "Insoluble Drug Solubilization Technology Platform", "Sustained and Controlled Release Drug Preparation Research and Development Platform" and "Fixed-dose Compound Drug Preparation Research and Development Platfor.
According to the prospectus of Xuantai Pharmaceuticals, Xuantai Pharmaceuticals plans to issue 434 million shares in an initial public offering and raise 600 million yuan, which will be mainly used for the preparation production complex building and related supporting facilities projects, high-end generic drugs and improved new drug research and development projects and supplementary Liquidi.
The fundraising project aims to increase the company's production capacity, improve the technical level, enrich the product line, and provide financial suppo.
At the same time, the implementation of the project is also conducive to further enhancing the innovation and creativity of the company's existing products, thereby enhancing the company's sustainable profitability and overall competitivene.
It is understood that Xuantai Pharmaceutical has achieved rapid development in recent years under the background of favorable policies supported by the country's key support for the preparation indust.
The data shows that by the end of 2021, Xuantai Pharmaceutical has completed 4 ANDA applications and 6 NMPA applications for its self-developed products in the field of high-end generic drugs; the high-end generic drugs jointly developed by Xuantai have completed 2 ANDA applications and 3 NMPA applicatio.
, In addition, the company has a number of improved new drug projects under developme.
From the performance point of view, the data shows that from 2019 to 2021, Xuantai Pharmaceutical relies on core technologies to achieve main business income of 138 million yuan, 316 million yuan and 314 million yuan respective.
United Imaging Medical is an enterprise that designs, develops, produces and sells high-end medical imaging diagnostic products, radiotherapy products and high-end life science instruments, and provides supporting intelligent and information-based solutio.
The company has outstanding scientific research strength, and has invested more than 5 billion yuan in research and development in the past three yea.
According to the prospectus of United Imaging Medical, it plans to raise funds of 148 billion yuan this time, which will be used for next-generation product research and development projects, high-end medical imaging equipment industrialization fund projects, informatization improvement projects and supplementary working capital, e.
, to further support the company's future developme.
Scale and globalization, expand the company's high-end medical imaging equipment production capacity, accelerate the company's product and technology upgrades, improve the localization level of core components, and expand the company's domestic and foreign marke.
It is understood that United Imaging Medical has already deployed production capacity in Shanghai, Changzhou, Wuhan, Houston, USA, e.
It has also set up future laboratories at its Shanghai headquarters and Houston, USA, focusing on the pre-research, cross-border and advanced technology of next-generation imaging and treatment equipme.
Industry technological breakthroughs and their innovative applications in the medical fie.
In terms of globalization, since 2018, the proportion of overseas revenue in United Imaging's main business has shown an increasing trend year by ye.
United Imaging Medical has obtained FDA certificates for 22 products and CE certificates for 34 produc.
In terms of performance, from 2019 to 2021, the compound growth rate of United Imaging Medical's operating income reached 50
In the past three years, the company's operating income was 980 billion yuan, 761 billion yuan, and 254 billion yuan respective.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
